Erratum: Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: A double-blind, Placebo-controlled, randomized study (International Journal of Impotence Research (2010) 22 (325-335) DOI: 10.1038/ijir.2010.23);Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: A double-blind, placebo-controlled, randomized study

International Journal of Impotence Research

Volumn 22, Issue 5, 2010, Pages 325-335

  Safarinejad, M R ^a   Taghva, A ^b   Shekarchi, B ^b   Safarinejad, Sh ^a  

^a Private Practice of Urology and Andrology   (Iran)

^b AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

erectile dysfunction; Parkinson; sexual dysfunction; sildenafil; treatment

Indexed keywords

PLACEBO; SILDENAFIL;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; COLOR VISION DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; HEMODYNAMICS; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NOSE CONGESTION; PARKINSON DISEASE; PHOTOPHOBIA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEXUAL FUNCTION;

EID: 77958186823     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2011.11     Document Type: Erratum

References (38)

1. Benito-Leon J, Bermejo-Pareja F, Rodriguez J, Molina J-A, Gabriel R, Morales J-M. Prevalence of PD and other types of Parkinsonism in three elderly populations of central Spain. Mov Disord 2003;18:267-274. (Pubitemid 36410822)
2. Hamani C, Lozano AM. Physiology and pathophysiology of Parkinson's disease. Ann NYAcad Sci 2003;991:15-21.
3. Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson's disease. Urology 2006;67:447-451.
4. Bronner G, Royter V, Korczyn AD, Giladi N. Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 2004;30:95-105.
5. Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson's disease patients and normal control. Parkinsonism Relat Disord 2003;10:67-71.
6. Mostilea G, Jankovica J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009;15S3: S224-S232.
7. Meco G, Rubino A, Caravona N, Valente M. Sexual dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2008;14:451-456.
8. Moore O, Gurevich T, Korczyn AD, Anca M, Shabtai H, Giladi N. Quality of sexual life in Parkinson's disease. Parkinsonism Relat Disord 2002;8:243-246.
9. Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002;41:382-386. (Pubitemid 35333932)
10. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000;15:305-308.
11. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-374.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
13. Hoehn MM, Yahr MD. Parkinsonism: onset progression and mortality. Neurology 1967;17:427-442.
14. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatry Association: Washington, DC, 1994.
15. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TB (eds). Geriatric Psychiatry. Grune and Stratton: New York, 1976, pp 77-121.
16. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) guidelines. Available at: http://www.ich.org. Last accessed 30 January 2007.
17. Montorsi F, Guazzoni G, Bergamaschi F, Consonni P, Rigatti P, Pizzini G et al. Vascular abnormalities in Peyronie's disease: the role of color Doppler sonography. J Urol 1994;151:373-375.
18. Wilkins CJ, Sriprasad S, Sidhu PS. Colour Doppler ultrasound of the penis. Clin Radiol 2003;58:514-523.
19. Rosen RC, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
20. Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999;53:793-799.
21. Fleiss J. The Design and Analysis of Clinical Experiments. John Wiley & Sons: New York, NY, 1986;49-51.
22. Fugl-Meyer AR, Lodnert G, Bränholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997;9:141-148.
23. Lewis RB, Bennett CJ, Borkon WD, Boykin WH, Althof SE, Stecher VJ et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology 2001;57:960-965.
24. Melis MR, Argiolas A. Dopamine and sexual behavior. Neurosci Biobehav Rev 1995;19:19-38.
25. Singer C, Weiner WJ, Sanchez-Ramos JR, Ackerman M. Sexual dysfunction in men with Parkinson's disease. J Neurol Rehabil 1989;3:199-204.
26. Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatr 1990;53:480-486.
27. Goodwin FK, Murphy DL, Brodie HK, Bunney Jr WE. Levodopa: alterations in behavior. Clin Pharmacol Ther 1971;12:383-396.
28. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol Jul. 2006;63:969-973.
29. Harvey NS. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry 1988;153:833-836.
30. Hand A, Gray WK, Chandler BJ, Walker RW. Sexual and relationship dysfunction in people with Parkinson's disease. Parkinsonism Relat Disord 2009;16:172-176.
31. Meco G, Rubino A, Caravona N, Valente M. Sexual dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2008;14:451-456.
32. Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabetes Complications 2004;18:205-210.
33. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-426.
34. Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009;181:252-258.
35. Safarinejad MR, Kolahi AA, Ghaedi G. Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a doubleblind, randomized and placebo-controlled study. BJU Int 2009;104:376-383.
36. Levinson IP, Creanga DL. Appropriate starting dose of VIAGRA1 (sildenafil citrate) for the treatment of erectile dysfunction: pooled analysis of flexible-dose, placebo controlled, double-blind studies and open-label extension. J Sex Med 2005;2(Suppl 1):36.
37. Padma-Nathan H, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 1998;52:375-379.
38. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999;162:722-725.